The acquisition of the Czech firms UNICAplasma sro and UNICAplasma Morava sro, which run five plasma collection centres in the Czech Republic, was announced by Kedrion, an Italian global biopharmaceutical company that collects and fractionates blood plasma to make and distribute plasma-derived drugs for the treatment of serious diseases and conditions.
These facilities, which can collect 70,000 litres of waste per year, are run under two different names throughout the Czech Republic: UNICAplasma in Prague and Mojeplazma in Kladno, Ostrava, Frydek-Mistek, and Cesky Tesin.
“We are convinced that this acquisition will significantly improve the value of our business and allow us to take part in plasma collection in Europe”, Thanks to this operation, we will be able to guarantee for our production plants an increasing quantity of high quality plasma, this unique and specific raw material for the production of plasma-derived products crucial to prevent and treat rare and debilitating diseases”.
Paolo Marcucci , CEO of Kedrion
Kedrion, an international biopharmaceutical company with its headquarters in Italy that collects and fractionates blood plasma to create and distribute plasma-derived drugs for the treatment of serious illnesses and conditions, announced the acquisition of the Czech firms UNICAplasma sro and UNICAplasma Morava sro, which run five plasma collection facilities in the Czech Republic.
These facilities, which can collect 70,000 litres of waste per year, operate across the entire territory of the Czech Republic under two separate brand names: UNICAplasma in Prague and Mojeplazma in Kladno, Ostrava, Frydek-Mistek, and Cesky Tesin.
